"Researchers discovered that the protein NFIL3 weakens CAR T cells over time. Disabling NFIL3 using CRISPR/Cas9 allows CAR T cells to remain active longer and attack tumors more effectively. This finding could improve cancer treatment, particularly for solid tumors."